EULAR 2020: Biosimilar Adalimumab Proves Comparable to the Branded Version in Rheumatoid Arthritis
Efficacy, safety, and immunogenicity were similar between the two products.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.